Padnarsertib

N/A

Report date: 2024/05/02 20:00:03
NME

Base Information

Drug NamePadnarsertib
Drug Alias NameKPT-9274ATG-019KCP-9274
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase PAK 4 inhibitorsNicotinamide phosphoribosyltransferase inhibitors
TargetsSerine/threonine-protein kinase PAK 4Nicotinamide phosphoribosyltransferase
Therapy Area/IndicationsSolid tumoursLymphoma, Non-HodgkinLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesKaryopharm Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesKaryopharm Therapeutics IncUniversity Of Colorado Denver
Inactive CompaniesAntengene Therapeutics LtdEmerson Resources IncAntengene Corporation (Shanghai) Ltd
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsSolid tumoursLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A